60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 257,700 shares, an increase of 412.3% from the November 30th total of 50,300 shares. Currently, 13.9% of the shares of the company are sold short. Based on an average daily volume of 307,300 shares, the days-to-cover ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday.

60 Degrees Pharmaceuticals Trading Down 5.8 %

Shares of SXTP stock traded down $0.08 on Friday, hitting $1.26. The stock had a trading volume of 60,924 shares, compared to its average volume of 284,843. The firm has a market cap of $2.90 million, a P/E ratio of -0.13 and a beta of 5.36. 60 Degrees Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $15.00. The company has a fifty day moving average price of $1.11 and a two-hundred day moving average price of $0.92.

Insider Transactions at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow bought 35,823 shares of 60 Degrees Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were acquired at an average cost of $1.27 per share, with a total value of $45,495.21. Following the acquisition, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. The trade was a 60.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have acquired 66,372 shares of company stock worth $82,410. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.